Bristol-Myers claims the lead in a race to develop a TYK2 drug, hoping to disrupt a huge market for anti-inflammatories
Bristol-Myers Squibb’s TYK2 team has been showing off some Phase II data they believe puts them in the running for leader of a small but prominent pack of developers looking to advance a new class of anti-inflammatories that aim at penetrating some very big markets.
As published in the New England Journal of Medicine and presented at the 27th European Academy of Dermatology and Venerology Congress in Paris, Bristol-Myers’ effort for BMS-986165 produced some competitive results in a key mid-stage study for moderate-to-severe plaque psoriasis — a packed field where JAK inhibitors have been making waves.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.